ThisCART22
/ Fundamenta Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 04, 2021
Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
(clinicaltrials.gov)
- P1; N=20; Recruiting; Sponsor: Fundamenta Therapeutics, Ltd.
Clinical • New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22
October 23, 2020
Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies
(clinicaltrials.gov)
- P1; N=20; Recruiting; Sponsor: Fundamenta Therapeutics, Ltd.
Clinical • New P1 trial • Hematological Malignancies • Oncology
1 to 2
Of
2
Go to page
1